March 2018, Vol. 108, (3 Suppl 1)
2018
Vol.5 No.2:73
DOI: 10.21767/2254-9137.100092
Health Systems and Policy Research ISSN 2254-9137
PLOS ONE | https://doi.org/10.1371/journal.pone.0217693 June 7, 2019
Review
Drake AL et al. Journal of the International AIDS Society 2019, 22:e25271 http://onlinelibrary.wiley.com/doi/10.1002/jia2.25271/full | https://doi.org/10.1002/jia2.25271
AIDS Behav (2017) 21:S23–S33 DOI 10.1007/s10461-016-1670-9
Research Article
PLOS ONE | https://doi.org/10.1371/journal.pone.0192791 February 15, 2018
UNICEF’s Global HIV Response 2018 – 2021
Accessed: 02.11.2019
Global AIDS Update 2018
Closing Gaps
Breaking Barriers
Righting injustices
Guidance Brief
Selected findings from ECDC and EMCDDA scientific guidance, 2018
WHO Annual Meeting with Pharmaceutical Companies and Stakeholders
08 March 2016, Geneva
2015-06-03 - Board presentation - v32.pptx
EClinicalMedicine 1 (2018) 21–27
https://doi.org/10.1016/j.eclinm.2018.06.005
2589-5370/© 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
EClinicalMedicine: journal homepage: https://www.jo...urnals.elsevier.com/ eclinicalmedicine
Research Paper
more
WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely reported among PrEP users who tested HIV positive i...n randomized controlled trials or open-label studies. However, PrEP-selected HIV drug resistance could potentially negatively impact the effectiveness of treatment options among PrEP users who acquire HIV, since there is a potential for overlapping resistance profiles between antiretroviral drugs used for both PrEP and first-line antiretroviral therapy.
more
UNAIDS/WHO 2015 | Reference
PQDx 0053-006-00 WHO
PQ Public Report
June/2016, version 2.0